{"id":829790,"date":"2025-03-25T19:03:13","date_gmt":"2025-03-25T23:03:13","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/biomea-fusion-announces-leadership-transition\/"},"modified":"2025-03-25T19:03:13","modified_gmt":"2025-03-25T23:03:13","slug":"biomea-fusion-announces-leadership-transition","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/biomea-fusion-announces-leadership-transition\/","title":{"rendered":"Biomea Fusion Announces Leadership Transition"},"content":{"rendered":"<div class=\"mw_release\">\n<p align=\"center\">\n        <em>Board member Mick Hitchcock, named interim CEO replacing Thomas Butler.<\/em>\n      <\/p>\n<p align=\"center\">\n        <em>COO and President Ramses Erdtmann continuing at Biomea in current role.<\/em>\n      <\/p>\n<p>REDWOOD CITY, Calif., March  25, 2025  (GLOBE NEWSWIRE) &#8212; \u00a0Biomea Fusion, Inc. (\u201cBiomea,\u201d or the \u201cCompany\u201d) (Nasdaq: BMEA), a clinical-stage diabetes and obesity medicines company, announced today an executive leadership change to help ensure the company realizes its full potential developing a novel therapy for diabetes. Specifically, Mick Hitchcock, a current board member since 2021, will succeed Thomas Butler as interim Chief Executive Officer. The change is effective immediately.<\/p>\n<p>\u201cAs a long-time member of Biomea\u2019s Board, I\u2019ve had the privilege of closely supporting the company\u2019s mission and strategic direction,\u201d said Michael J.M. Hitchcock, Ph.D., Interim Chief Executive Officer and Board Member of Biomea Fusion. \u201cI\u2019m honored to step into this leadership role at such a promising moment in our development. The recent clinical progress with icovamenib, especially the positive Phase II data in insulin-deficient patients, marks a major milestone in our pursuit of a disease-modifying therapy for diabetes. I look forward to working even more closely with the exceptional Biomea team as we advance late-stage development efforts, prepare for regulatory engagement, and continue building a pipeline of innovative covalent therapies. Our mission remains clear: We aim to cure, and I\u2019m committed to helping lead us there.\u201d<\/p>\n<p>Dr. Michael J. M. Hitchcock, Ph.D. (Mick) has served as a member of the Company\u2019s board since March 2021. Dr. Hitchcock is currently a Past Chair of the University of Nevada, Reno (UNR) Foundation and Adjunct Professor of Microbiology at UNR Medical School, a position in which he has served since July 2016. Dr Hitchcock\u2019s career in pharmaceutical research and development initially began with Bristol-Myers Squibb, where he served in several infectious disease research and project planning roles from 1980 through 1993. He joined Gilead Sciences, Inc. in 1993 and during his 27 years with the Company, he held a variety of positions, including vice president roles with responsibility for project and portfolio management, alliance management, strategic planning, medical affairs and specific areas of research. He also served as Senior Advisor at Gilead from 2009 through November 2019. During his career, he was involved in the development and commercialization of a number of anti-infective agents, primarily antivirals for treatment of HIV, HBV, influenza, CMV and other viral diseases. Dr. Hitchcock holds a Ph.D. in microbiology from the University of Melbourne, Australia and B.Sc. and M.Sc. degrees in biochemistry from the University of Manchester Institute of Science and Technology, England. He also conducted post-doctoral research at Georgetown University and NIH prior to joining industry.<\/p>\n<p>Biomea continues to develop its product candidates for the treatment of diabetes based on its novel menin inhibition science.<\/p>\n<p>\u201cOn behalf of the Board, we would like to thank Tom Butler for his important contributions to Biomea and his leadership to date,\u201d said Dr. Hitchcock.<\/p>\n<p>\n        <strong>About Biomea Fusion<\/strong><br \/>\n        <br \/>Biomea is a clinical-stage diabetes and obesity medicines company focused on the discovery and development of oral covalent small molecules to improve the lives of patients with diabetes, obesity, and metabolic disease. A covalent small molecule is a synthetic compound that forms a permanent bond to its target protein and offers a number of potential advantages over conventional non-covalent drugs, including greater target selectivity, lower drug exposure, and the ability to drive a deeper, more durable response.<\/p>\n<p>We are utilizing our proprietary FUSION\u2122 System to discover, design and develop a pipeline of next-generation covalent-binding small-molecule medicines designed to maximize clinical benefit for patients. We aim to have an outsized impact on the treatment of disease for the patients we serve. We aim to cure.<\/p>\n<p>Visit us at biomeafusion.com and follow us on <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=7lOZkc3K8DBImhr0ijK1GQRdyM0iXpFaagLrBdKL3Hpciz_6QDZbQhe_R906GZMKevF6LUsKv7wYGe6Z8bVgO2_cKMmbm5lk7CIm92mhS3qcQtZ8uhSFWFkFlrmO42pd\" rel=\"nofollow\" target=\"_blank\">LinkedIn<\/a>, <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=sC1sZh7HHYBbmEI2Xf66qiUv1VRAojH77ljoA8kW8xJwnYfSF-hPPPJlbthIzJQ8QEKb7HoqBanGCSSSlTaCFw==\" rel=\"nofollow\" target=\"_blank\">X<\/a><u>\u00a0<\/u>and <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=SAbqJ8NgWL_W2UCeOCZjrsOXfkH6fpsopUChQLrre0Ftyk8w7Td2aV3aovAF3yYCLSjOIBLIvEsdOIYk2HAwDtgnEL1XVGdaL4u9HJyFhXY=\" rel=\"nofollow\" target=\"_blank\">Facebook<\/a>.\u00a0<\/p>\n<p><strong>Contact<\/strong><strong>: <\/strong>\u00a0<br \/>Meichiel Jennifer Weiss \u00a0<br \/>Sr. Director, Investor Relations and Corporate Development<br \/>IR@biomeafusion.com\u00a0\u00a0<\/p>\n<p>      <img decoding=\"async\" alt=\"\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTQxMDg0MyM2ODM0MDg0IzIyMDg1NzI=\" \/><br \/>\n      <br \/>\n      <img decoding=\"async\" alt=\"\" src=\"https:\/\/ml.globenewswire.com\/media\/MzRkNzVmYTQtNzI5YS00M2U1LTk4MTAtMjlhNWQzMGFjYzdjLTEyMjAxMjUtMjAyNS0wMy0yNS1lbg==\/tiny\/Biomea-Fusion-Inc-.png\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>Board member Mick Hitchcock, named interim CEO replacing Thomas Butler. COO and President Ramses Erdtmann continuing at Biomea in current role. REDWOOD CITY, Calif., March 25, 2025 (GLOBE NEWSWIRE) &#8212; \u00a0Biomea Fusion, Inc. (\u201cBiomea,\u201d or the \u201cCompany\u201d) (Nasdaq: BMEA), a clinical-stage diabetes and obesity medicines company, announced today an executive leadership change to help ensure the company realizes its full potential developing a novel therapy for diabetes. Specifically, Mick Hitchcock, a current board member since 2021, will succeed Thomas Butler as interim Chief Executive Officer. The change is effective immediately. \u201cAs a long-time member of Biomea\u2019s Board, I\u2019ve had the privilege of closely supporting the company\u2019s mission and strategic direction,\u201d said Michael J.M. Hitchcock, Ph.D., Interim Chief Executive Officer and &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/biomea-fusion-announces-leadership-transition\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Biomea Fusion Announces Leadership Transition&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-829790","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.4 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Biomea Fusion Announces Leadership Transition - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/biomea-fusion-announces-leadership-transition\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Biomea Fusion Announces Leadership Transition - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"Board member Mick Hitchcock, named interim CEO replacing Thomas Butler. COO and President Ramses Erdtmann continuing at Biomea in current role. REDWOOD CITY, Calif., March 25, 2025 (GLOBE NEWSWIRE) &#8212; \u00a0Biomea Fusion, Inc. (\u201cBiomea,\u201d or the \u201cCompany\u201d) (Nasdaq: BMEA), a clinical-stage diabetes and obesity medicines company, announced today an executive leadership change to help ensure the company realizes its full potential developing a novel therapy for diabetes. Specifically, Mick Hitchcock, a current board member since 2021, will succeed Thomas Butler as interim Chief Executive Officer. The change is effective immediately. \u201cAs a long-time member of Biomea\u2019s Board, I\u2019ve had the privilege of closely supporting the company\u2019s mission and strategic direction,\u201d said Michael J.M. Hitchcock, Ph.D., Interim Chief Executive Officer and &hellip; Continue reading &quot;Biomea Fusion Announces Leadership Transition&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/biomea-fusion-announces-leadership-transition\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2025-03-25T23:03:13+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTQxMDg0MyM2ODM0MDg0IzIyMDg1NzI=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/biomea-fusion-announces-leadership-transition\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/biomea-fusion-announces-leadership-transition\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Biomea Fusion Announces Leadership Transition\",\"datePublished\":\"2025-03-25T23:03:13+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/biomea-fusion-announces-leadership-transition\\\/\"},\"wordCount\":635,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/biomea-fusion-announces-leadership-transition\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTQxMDg0MyM2ODM0MDg0IzIyMDg1NzI=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/biomea-fusion-announces-leadership-transition\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/biomea-fusion-announces-leadership-transition\\\/\",\"name\":\"Biomea Fusion Announces Leadership Transition - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/biomea-fusion-announces-leadership-transition\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/biomea-fusion-announces-leadership-transition\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTQxMDg0MyM2ODM0MDg0IzIyMDg1NzI=\",\"datePublished\":\"2025-03-25T23:03:13+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/biomea-fusion-announces-leadership-transition\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/biomea-fusion-announces-leadership-transition\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/biomea-fusion-announces-leadership-transition\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTQxMDg0MyM2ODM0MDg0IzIyMDg1NzI=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTQxMDg0MyM2ODM0MDg0IzIyMDg1NzI=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/biomea-fusion-announces-leadership-transition\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Biomea Fusion Announces Leadership Transition\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Biomea Fusion Announces Leadership Transition - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/biomea-fusion-announces-leadership-transition\/","og_locale":"en_US","og_type":"article","og_title":"Biomea Fusion Announces Leadership Transition - Market Newsdesk","og_description":"Board member Mick Hitchcock, named interim CEO replacing Thomas Butler. COO and President Ramses Erdtmann continuing at Biomea in current role. REDWOOD CITY, Calif., March 25, 2025 (GLOBE NEWSWIRE) &#8212; \u00a0Biomea Fusion, Inc. (\u201cBiomea,\u201d or the \u201cCompany\u201d) (Nasdaq: BMEA), a clinical-stage diabetes and obesity medicines company, announced today an executive leadership change to help ensure the company realizes its full potential developing a novel therapy for diabetes. Specifically, Mick Hitchcock, a current board member since 2021, will succeed Thomas Butler as interim Chief Executive Officer. The change is effective immediately. \u201cAs a long-time member of Biomea\u2019s Board, I\u2019ve had the privilege of closely supporting the company\u2019s mission and strategic direction,\u201d said Michael J.M. Hitchcock, Ph.D., Interim Chief Executive Officer and &hellip; Continue reading \"Biomea Fusion Announces Leadership Transition\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/biomea-fusion-announces-leadership-transition\/","og_site_name":"Market Newsdesk","article_published_time":"2025-03-25T23:03:13+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTQxMDg0MyM2ODM0MDg0IzIyMDg1NzI=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/biomea-fusion-announces-leadership-transition\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/biomea-fusion-announces-leadership-transition\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Biomea Fusion Announces Leadership Transition","datePublished":"2025-03-25T23:03:13+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/biomea-fusion-announces-leadership-transition\/"},"wordCount":635,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/biomea-fusion-announces-leadership-transition\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTQxMDg0MyM2ODM0MDg0IzIyMDg1NzI=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/biomea-fusion-announces-leadership-transition\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/biomea-fusion-announces-leadership-transition\/","name":"Biomea Fusion Announces Leadership Transition - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/biomea-fusion-announces-leadership-transition\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/biomea-fusion-announces-leadership-transition\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTQxMDg0MyM2ODM0MDg0IzIyMDg1NzI=","datePublished":"2025-03-25T23:03:13+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/biomea-fusion-announces-leadership-transition\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/biomea-fusion-announces-leadership-transition\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/biomea-fusion-announces-leadership-transition\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTQxMDg0MyM2ODM0MDg0IzIyMDg1NzI=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTQxMDg0MyM2ODM0MDg0IzIyMDg1NzI="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/biomea-fusion-announces-leadership-transition\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Biomea Fusion Announces Leadership Transition"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/829790","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=829790"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/829790\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=829790"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=829790"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=829790"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}